[1]
Fang, E.F.; Ng, T.B. Chapter 27 Achievements, questions arising and future outlook on the path to discover new medicinal compounds.In: Fang, E.F.; Ng, T.B. (Eds.) Antitumor potential and other emerging medicinal properties of natural compounds; Springer: Dordrecht, 2013.
[2]
Fang, E.F.; Ng, T.B. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim. Biophys. Acta, 2011, 1815, 65-74.
[3]
Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
[4]
Bauer, R.; Guo, D.A.; Hylands, P.; Fan, T.P.; Xu, Q. Chapter 25: The role of the GP-TCM research association to modernization and globalization of traditional Chinese Medicine. In: Fang, E.F.; Ng, T.B. (Eds.) Antitumor potential and other emerging medicinal properties of natural compounds; Springer: Dordrecht, 2013.
[5]
Fang, E.F.; Ng, T.B. Bitter gourd (Momordica charantia) is a cornucopia of health: A review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr. Mol. Med., 2011, 11, 417-436.
[6]
Fang, E.F.; Ng, T.B. Can bitter gourd (Momordica charantia) be a novel therapy for human cancers? Med. Aromat. Plants, 2012, 1, 1-2.
[7]
Zhang, C.Z.; Fang, E.F.; Zhang, H.T.; Liu, L.L.; Yun, J.P. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest. New Drugs, 2015, 33(1), 1-11.
[8]
Pan, W.L.; Wong, J.H.; Fang, E.F.; Chan, Y.S.; Ng, T.B.; Cheung, R.C. Preferential cytotoxicity of the type I ribosome inactivating protein alpha-momorcharin on human nasopharyngeal carcinoma cells under normoxia and hypoxia. Biochem. Pharmacol., 2014, 89, 329-339.
[9]
Fang, E.F.; Zhang, C.Z.; Wong, J.H.; Shen, J.Y.; Li, C.H.; Ng, T.B. The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Lett., 2012, 324, 66-74.
[10]
Fang, E.F.; Zhang, C.Z.; Zhang, L.; Fong, W.P.; Ng, T.B. In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int. J. Biochem. Cell Biol., 2012, 44, 1351-1360.
[11]
Fang, E.F.; Ng, T.B. Chapter 21: The bitter fruit with sweet health benefits: A comprehensive synopsis of recent research progress on medicinal properties of momordica charantia. In: Fang, E.F.; Ng, T.B. (Eds.) Antitumor potential and other emerging medicinal properties of natural compounds; Dordrecht, 2013.
[12]
Wong, C.M.; Yeung, H.W.; Ng, T.B. Screening of Trichosanthes kirilowii, Momordica charantia and Cucurbita maxima (family Cucurbitaceae) for compounds with antilipolytic activity. J. Ethnopharmacol., 1985, 13, 313-321.
[13]
Jilka, C.; Strifler, B.; Fortner, G.W.; Hays, E.F.; Takemoto, D.J. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res., 1983, 43, 5151-5155.
[14]
Ray, R.B.; Raychoudhuri, A.; Steele, R.; Nerurkar, P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res., 2010, 70, 1925-1931.
[15]
Kwatra, D.; Subramaniam, D.; Ramamoorthy, P.; Standing, D.; Moran, E.; Velayutham, R.; Mitra, A.; Umar, S.; Anant, S. Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid. Based Complement. Alternat. Med., 2013, 2013, 702869.
[16]
Kaur, M.; Deep, G.; Jain, A.K.; Raina, K.; Agarwal, C.; Wempe, M.F.; Agarwal, R. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cell. Carcinogenesis, 2013, 34, 1585-1592.
[17]
Somasagara, R.R.; Deep, G.; Shrotriya, S.; Patel, M.; Agarwal, C.; Agarwal, R. Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells. Int. J. Oncol., 2015, 46, 1849-1857.
[18]
Fang, E.F.; Zhang, C.Z.; Ng, T.B.; Wong, J.H.; Pan, W.L.; Ye, X.J.; Chan, Y.S.; Fong, W.P. Momordica charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev. Res. (Phila.), 2012, 5, 109-121.
[19]
Fan, J.M.; Luo, J.; Xu, J.; Zhu, S.; Zhang, Q.; Gao, D.F.; Xu, Y.B.; Zhang, G.P. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. Mol. Biotechnol., 2008, 39, 79-86.
[20]
Lee-Huang, S.; Huang, P.L.; Lee-Huang, P. Chapter 8: The discovery of MAP30 and elucidation of its medicinal activities.In: Fang, E.F.; Ng T.B.; (Eds.)Antitumor potential and other emerging medicinal properties of natural compounds; Dordrecht, 2013.
[21]
Xiong, S.D.; Yu, K.; Liu, X.H.; Yin, L.H.; Kirschenbaum, A.; Yao, S.; Narla, G.; DiFeo, A.; Wu, J.B.; Yuan, Y.; Ho, S.M.; Lam, Y.W.; Levine, A.C. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int. J. Cancer, 2009, 125, 774-782.
[22]
Fang, E.F.; Zhang, C.Z.; Fong, W.P.; Ng, T.B. RNase MC2: A new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis, 2012, 17, 377-387.
[23]
Weng, J.R.; Bai, L.Y.; Chiu, C.F.; Hu, J.L.; Chiu, S.J.; Wu, C.Y. Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor gamma activation. Evid. Based Complement. Alternat. Med., 2013, 2013, 935675.
[24]
Zhang, C.Z.; Fang, E.F.; Zhang, H.T.; Liu, L.L.; Yun, J.P. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest. New Drugs, 2015, 33, 1-11.
[25]
Marino, G.; Niso-Santano, M.; Baehrecke, E.H.; Kroemer, G. Self-consumption: The interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol., 2014, 15, 81-94.